Fernández I, Castellano G, Domingo M J, Fuertes A, Colina F, Canga F, de la Cruz F J, de la Cámara A G, Solís J A
Dept. of Gastroenterology, Doce de Octubre Hospital, Madrid, Spain.
Scand J Gastroenterol. 1997 Jan;32(1):70-6. doi: 10.3109/00365529709025066.
We wanted to investigate the influence of viral genotype on the severity of liver injury and response to interferon and whether the level of viremia differs in accordance with genotype, severity of liver disease, and response to interferon in patients with hepatitis C virus (HCV) infection.
We studied 118 patients with HCV-related liver disease. HCV genotypes were determined with a line probe assay, and serum HCV RNA levels with a competitive reverse transcription polymerase chain reaction assay.
HCV type 1b was the most prevalent genotype (88%). It was present in 100% of cirrhotic patients, with or without hepatocellular carcinoma (HCC), but only in 78% of patients with chronic hepatitis (P < 0.001). The response to interferon was better in patients infected with non-1b HCV genotypes (P = 0.002). In a multivariate analysis non-1b HCV genotypes and a low hepatic fibrosis correlated with a favorable response to interferon. Among patients with chronic hepatitis those infected with HCV type 1b were older (P < 0.001), and age was the only independent factor associated with HCV type 1b. Viremia levels differed neither between genotypes nor in response to interferon and was significantly lower in patients with cirrhosis and HCC.
HCV 1b was associated with more severe liver disease and a worse response to interferon therapy. Non-1b genotypes and a lower liver fibrosis were the only independent predictors of a favorable response to interferon. Levels of HCV viremia differed neither among different genotypes nor in response to interferon and decreased with advanced liver disease.
我们想要研究病毒基因型对肝损伤严重程度及对干扰素反应的影响,以及丙型肝炎病毒(HCV)感染患者的病毒血症水平是否因基因型、肝病严重程度及对干扰素的反应而有所不同。
我们研究了118例HCV相关肝病患者。采用线性探针分析法确定HCV基因型,采用竞争性逆转录聚合酶链反应分析法测定血清HCV RNA水平。
HCV 1b型是最常见的基因型(88%)。在所有肝硬化患者中均存在,无论有无肝细胞癌(HCC),但仅在78%的慢性肝炎患者中存在(P<0.001)。感染非1b型HCV基因型的患者对干扰素的反应更好(P = 0.002)。多因素分析显示,非1b型HCV基因型和低肝纤维化与对干扰素的良好反应相关。在慢性肝炎患者中,感染HCV 1b型的患者年龄更大(P<0.001),年龄是与HCV 1b型相关的唯一独立因素。病毒血症水平在不同基因型之间以及对干扰素的反应中均无差异,在肝硬化和HCC患者中显著降低。
HCV 1b型与更严重的肝病及对干扰素治疗的更差反应相关。非1b型基因型和较低的肝纤维化是对干扰素良好反应的唯一独立预测因素。HCV病毒血症水平在不同基因型之间以及对干扰素的反应中均无差异,并随着肝病进展而降低。